Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis Spin-Off Novexel Gains Indevus’ Antifungal Aminocandin

This article was originally published in The Pink Sheet Daily

Executive Summary

Novexel is solely focused on developing anti-infective compounds such as the Phase I compound aminocandin.

You may also be interested in...

Indevus Gains Supprelin LA With Purchase Of Valera

Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.

Noxafil Gains Additional Oropharyngeal Candidiasis Indication

Approval for Schering-Plough’s antifungal comes just one month after FDA cleared it for invasive Aspergillus and Candida infections.

Noxafil Is First FDA-Approved Antifungal For Aspergillus Infection Prevention

Schering-Plough plans to launch posaconazole for patients at high risk within two weeks.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts